Zobrazeno 1 - 10
of 19
pro vyhledávání: '"M N, Raber"'
Publikováno v:
Annals of Oncology. 9:1003-1008
Summary Background: The long intracellular half-life of gemcitabine's active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), suggested that small increases in peak intracellular dFdCTP levels would have a profound effect on its intracellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b01c1418118256dadfe2eaed22997524
https://doi.org/10.1023/a:1008487932384
https://doi.org/10.1023/a:1008487932384
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(11)
The clinical features and survival times of patients with unknown primary carcinoma (UPC) are heterogeneous. Therefore, the goals of this study were to apply a novel analytical method to UPC patients to: (a) identify novel prognostic factors; (b) exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74de84af948f025f5a51ac0ef2683ff3
https://pubmed.ncbi.nlm.nih.gov/10589751
https://pubmed.ncbi.nlm.nih.gov/10589751
Autor:
J L, Abbruzzese, T, Madden, S M, Sugarman, A L, Ellis, S, Loughlin, K R, Hess, R A, Newman, L A, Zwelling, M N, Raber
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(9)
Topotecan, a semisynthetic water-soluble analogue of camptothecin, inhibits human topoisomerase I (topo I). We performed a Phase I clinical and plasma pharmacological study of topotecan administered by 24-h continuous infusion without and with granul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13513177d7c795db438cfe2aaba0338b
https://pubmed.ncbi.nlm.nih.gov/9816325
https://pubmed.ncbi.nlm.nih.gov/9816325
Publikováno v:
International Journal of Oncology.
Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m(2) of 5-aza-CdR and 75 mg/m(2) of cDDP. A response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d61dee50ad32fdd7eee0049a5ad3fff
https://doi.org/10.3892/ijo.6.2.447
https://doi.org/10.3892/ijo.6.2.447
Publikováno v:
Seminars in oncology. 20(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d5c0bf82d0e3cc02384945619e736c4
https://pubmed.ncbi.nlm.nih.gov/8503019
https://pubmed.ncbi.nlm.nih.gov/8503019
Publikováno v:
Anticancer research. 13(2)
FK 973, a novel substituted dihydrobenzoxazine structurally similar to mitomycin C, is a derivative of the product isolated from Streptomyces sandaensis. In vitro and in rodents, it is a potent antitumor agent. During Phase I clinical trials, we eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::40e166e5201b69f93bd685091c73687c
https://pubmed.ncbi.nlm.nih.gov/8517646
https://pubmed.ncbi.nlm.nih.gov/8517646
Autor:
D H, Ho, W P, Covington, R, Pazdur, N S, Brown, J, Kuritani, R A, Newman, M N, Raber, I H, Krakoff
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 20(6)
Phase I clinical trials of the combination of oral uracil with ftorafur (Ft) were conducted in patients with solid tumors over either a 5-day (345 mg/m2/day) or a 28-day (160 mg/m2/day) period. The uracil dose, which was four times the Ft dose (molar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::268743e09d45e4b33b1894806ea8c347
https://pubmed.ncbi.nlm.nih.gov/1362949
https://pubmed.ncbi.nlm.nih.gov/1362949
Publikováno v:
Cancer research. 52(6)
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a number of murine tumors including P388, L1210, B16 and M5076, as well as against MX1 and HCT116 xenografts. Preclinical toxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d694ed6257516bb878efbb1ed6586566
https://pubmed.ncbi.nlm.nih.gov/1540949
https://pubmed.ncbi.nlm.nih.gov/1540949
Publikováno v:
Current opinion in oncology. 4(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0beb9bcda89f2282ca8ff00be644e9e8
https://pubmed.ncbi.nlm.nih.gov/1591292
https://pubmed.ncbi.nlm.nih.gov/1591292
Autor:
R, Perez-Soler, G, Lopez-Berestein, J, Lautersztain, S, al-Baker, K, Francis, D, Macias-Kiger, M N, Raber, A R, Khokhar
Publikováno v:
Cancer research. 50(14)
cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum++ +(II) (NDDP) is a liposome dependent cisplatin analogue since the liposome carrier is required for its i.v. administration and for its biological activity. A Phase I study of liposome en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b36b8fa77672c47a7b1cbee679482d3d
https://pubmed.ncbi.nlm.nih.gov/2364384
https://pubmed.ncbi.nlm.nih.gov/2364384